摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-chloro-3-nitrophenyl)benzo[d]thiazole

中文名称
——
中文别名
——
英文名称
2-(4-chloro-3-nitrophenyl)benzo[d]thiazole
英文别名
2-(4-Chloro-3-nitrophenyl)-1,3-benzothiazole
2-(4-chloro-3-nitrophenyl)benzo[d]thiazole化学式
CAS
——
化学式
C13H7ClN2O2S
mdl
MFCD01974110
分子量
290.73
InChiKey
XPXYSCQMADQBFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    87
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-chloro-3-nitrophenyl)benzo[d]thiazole 在 palladium 10% on activated carbon 、 potassium carbonate 作用下, 以 乙醇二甲基亚砜 为溶剂, 反应 8.5h, 生成 4-benzothiazol-2-yl-N1-phenylbenzene-1,2-diamine
    参考文献:
    名称:
    Synthesis and Biological Evaluation of Analogues of AKT (Protein Kinase B) Inhibitor-IV
    摘要:
    Inhibitors of the PI3-kinase/AKT (protein kinase B) pathway are under investigation as anticancer and antiviral agents. The benzimidazole derivative AKT inhibitor-IV (ChemBridge 5233705) affects this pathway and exhibits potent anticancer and antiviral activity. To probe its biological activity, we synthesized AKT inhibitor-IV and 21 analogues using a novel six-step route based on ZrCl4-catalyzed cyclization of 1,2-arylenediamines with alpha,beta-unsaturated aldehydes. We examined effects on viability of HeLa carcinoma cells, viability of normal human cells (NHBE), replication of recombinant parainfluenza virus 5 (PIV5) in HeLa cells, and replication of the intracellular bacterium Mycobacterium fortuitum in HeLa cells. Replacement of the benzimidazole N-ethyl substitutent of AKT inhibitor-IV with N-hexyl and N-dodecyl groups enhanced antiviral activity and cytotoxicity against the cancer cell line, but these compounds showed substantially lower toxicity (from 6-fold to >20-fold) against NHBE cells and no effect on M. fortuitum, suggesting inhibition of one or more host protein(s) required for proliferation of cancer cells and PIV5. The key structural elements identified here may facilitate identification of targets of this highly biologically active scaffold.
    DOI:
    10.1021/jm100912b
  • 作为产物:
    描述:
    2-(4-氯苯基)苯并噻唑silver(I) nitrite十二羰基三钌 、 tricyclohexylphosphine tetrafluoroborate 、 [双(三氟乙酰氧基)碘]苯三甲基乙酸 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 24.0h, 以56%的产率得到2-(4-chloro-3-nitrophenyl)benzo[d]thiazole
    参考文献:
    名称:
    The ruthenium-catalyzed meta-selective C–H nitration of various azole ring-substituted arenes
    摘要:

    我们开发了一种高效且温和的钌催化的对取代芳烃的唑环进行间位-选择性的CAr–H硝化的方法。

    DOI:
    10.1039/c9ob01930h
点击查看最新优质反应信息

文献信息

  • TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    申请人:Wynne Graham Michael
    公开号:US20090075938A1
    公开(公告)日:2009-03-19
    There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
    公式(1)的化合物被揭示:A1,A2,A3和A4,它们可以相同或不同,代表N或CR1,X是从O,S(O)n,C═W,NR4,NC(═O)R5和CR6R7中选择的二价基团,W是O,S,NR20,Y是N或CR8,R4,R5,R6,R8,R9和NR20中的一个表示-L-R3,在其中L是单键或连接基团,此外,R1,R3-R9可以相同或不同,独立地表示氢或取代基,R20表示氢,羟基,可以用芳基取代的烷基,可以用芳基取代的烷氧基,芳基,CN,可以用芳基取代的烷氧基,可以用芳基取代的芳氧基,可以用取代基取代的烷酰基,可以用取代基取代的芳酰基,NO2,NR30R31,在其中R30和R31可以相同或不同,表示氢,可选地取代的烷基或可选地取代的芳基;此外,R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基,n表示从0到2的整数,另外,当相邻的A1-A4中的一对表示CR1时,那么相邻的碳原子及其取代基可以形成环B,当X为CR6R7时,R6和R7与它们附着的碳原子一起可以形成环C,或其药学上可接受的盐,在制造用于治疗和/或预防杜氏肌萎缩症,贝克肌萎缩症或消瘦症的药物时使用。
  • Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
    申请人:Wynne Graham Michael
    公开号:US20110195932A1
    公开(公告)日:2011-08-11
    Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.
    本发明涉及与一种或多种化合物(1)的一个或多个辅助剂组合的组合物,以制备这些组合物的过程,以及这些组合物的各种治疗用途。还提供了包含这些组合物的制药组合物,以及使用这些组合物治疗杜氏肌营养不良症、贝克肌营养不良症或消瘦的方法。
  • DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    申请人:Summit Corporation PLC
    公开号:US20140011782A1
    公开(公告)日:2014-01-09
    Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.
    该专利涉及包含(或基本上由)一个或多个式(1)化合物和一个或多个辅助剂的组合物,以及制备这些组合物的方法,以及这些组合物的各种治疗用途。此外,还提供了包含这些组合物的药物组合物以及使用这些组合物治疗杜兴肌肉萎缩症,贝克肌肉萎缩症或消瘦症的方法。
  • Phenyliodonium diacetate mediated arylation of benzothiazoles with substituted styrenes
    作者:Ahmed Kamal、N.V. Subba Reddy、B. Prasad
    DOI:10.1016/j.tetlet.2014.05.019
    日期:2014.7
    A metal-free synthesis of 2-arylbenzothiazoles was achieved using phenyliodonium diacetate (PIDA) from benzothiazoles and styrenes or beta-nitrostyrenes. This transformation tolerates various functional groups such as methoxy, hydroxy, fluoro, chloro, and nitro groups. (C) 2014 Elsevier Ltd. All rights reserved.
  • Bogert; Conklin, Collection of Czechoslovak Chemical Communications, 1933, vol. 5, p. 443,446
    作者:Bogert、Conklin
    DOI:——
    日期:——
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑-d4 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺 苯并噻唑-2-基(对甲苯基)甲醇 苯并噻唑-2-乙酸甲酯 苯并噻唑-2-乙腈 苯并噻唑-2(3H)-酮N2-[1-(吡啶-4-基)乙亚基]腙 苯并噻唑-2 - 丙基 苯并噻唑,6-(3-乙基-2-三氮烯基)-2-甲基-(8CI)